Ascenta Therapeutics Highlights Multiple Data Presentations at This Week's AACR-NCI-EORTC International Conference in San Francisco.SAN DIEGO -- Ascenta Therapeutics, Inc. announced today that its small molecule portfolio of apoptosis-triggering compounds will be featured in two oral presentations and several poster presentations this week at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 22-26, 2007 at the Moscone Convention Center in San Francisco, CA. Preclinical studies of AT-101, Ascenta's oral pan-Bcl-2 inhibitor, currently in randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. Phase 2 trials, will be featured in 2 presentations, highlighting its activity in murine murine /mu·rine/ (mur´en) pertaining to, derived from, or characteristic of mice or rats. mu·rine adj. lung cancer models. Ascenta's collaborators at the University of Michigan (body, education) University of Michigan - A large cosmopolitan university in the Midwest USA. Over 50000 students are enrolled at the University of Michigan's three campuses. The students come from 50 states and over 100 foreign countries. will present data on the next generation of small molecule BH3 mimetics. Presentations will also cover Ascenta's inhibitors of the MDM (Modular Digital Multitrack) An audio recorder that mixes and records multiple tracks of digital audio. The two major MDM technologies are ADAT and DTRS. See ADAT and DTRS. 2 and XIAP XIAP X-linked Inhibitor of Apoptosis targets. The full schedule of presentations featuring Ascenta's technology is as follows: [TABLE OMITTED] Founded in 2003, Ascenta is a privately-held biopharmaceutical company that discovers and develops targeted new medicines for the treatment of cancer. The company has offices in Malvern, Pennsylvania and San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. and a preclinical research facility in Shanghai, China. Ascenta's technology is focused on discovering molecules that hit vulnerable targets in endogenous apoptosis pathways and shut down cell growth and proliferation in cancer cells. Ascenta's broad pipeline of compounds is licensed from both the National Institutes of Health and the laboratory of Dr. Shaomeng Wang at the University of Michigan. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion